Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas-ko ikertzaileekin lankidetzan egindako argitalpenak (41)

2022

  1. Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APPswe Alzheimer’s Disease Mouse Model

    International Journal of Molecular Sciences, Vol. 23, Núm. 7

  2. Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease

    Journal of Alzheimer's disease : JAD, Vol. 90, Núm. 2, pp. 719-726

2021

  1. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 2, pp. 324-333

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

  2. Reversal of Object Recognition Memory Deficit in Perirhinal Cortex-Lesioned Rats and Primates and in Rodent Models of Aging and Alzheimer's Diseases

    Neuroscience, Vol. 448, pp. 287-298

  3. Smelling the Dark Proteome: Functional Characterization of PITH Domain-Containing Protein 1 (C1orf128) in Olfactory Metabolism

    Journal of Proteome Research, Vol. 19, Núm. 12, pp. 4826-4843

2019

  1. Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson's disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model

    Frontiers in Immunology, Vol. 10, Núm. MAY

  2. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: A cross-sectional analysis from the AB255 Study

    Alzheimer's Research and Therapy, Vol. 11, Núm. 1

2018

  1. Adrenomedullin, a Novel Target for Neurodegenerative Diseases

    Molecular Neurobiology, Vol. 55, Núm. 12, pp. 8799-8814

  2. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

    Biochemical Pharmacology, Vol. 157, pp. 67-84

  3. Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimer’s Disease

    Molecular Neurobiology, Vol. 55, Núm. 6, pp. 5177-5183

  4. Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice

    Scientific Reports, Vol. 8, Núm. 1

  5. Reduced Adrenomedullin Parallels Microtubule Dismantlement in Frontotemporal Lobar Degeneration

    Molecular Neurobiology, Vol. 55, Núm. 12, pp. 9328-9333

2017

  1. Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1863, Núm. 4, pp. 991-1001

  2. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

    Neuropharmacology, Vol. 113, pp. 110-123

2016

  1. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease

    Brain, Behavior, and Immunity, Vol. 57, pp. 94-105

  2. Limited unfolded protein response and inflammation in neuroserpinopathy

    Journal of Neuropathology and Experimental Neurology, Vol. 75, Núm. 2, pp. 121-133

2015

  1. Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins

    Trends in Biochemical Sciences

2014

  1. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: A two-step process

    Brain, Vol. 137, Núm. 8, pp. 2356-2367

  2. Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes

    Neurobiology of Aging, Vol. 35, Núm. 11, pp. 2657.e13-2657.e19